Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.23 HKD | -0.24% |
|
-0.47% | -5.57% |
06-19 | Genertec Universal Medical Slashes Conversion Price of Convertible Bonds | MT |
06-05 | Genertec Universal Medical Group Completes Issuance of T4 Bonds in China | MT |
Strengths
- The company returns high margins, thereby supporting business profitability.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
- The company is one of the best yield companies with high dividend expectations.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Corporate Financial Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.57% | 1.02B | - | ||
+114.81% | 9.17B | D | ||
-6.95% | 4.82B | C | ||
+8.49% | 4.7B | C+ | ||
-2.59% | 4.47B | C+ | ||
+11.54% | 3.77B | - | - | |
+51.80% | 3.46B | - | C+ | |
-1.06% | 2.24B | - | ||
+15.70% | 1.91B | - | C- | |
+4.05% | 1.23B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 2666 Stock
- Ratings Genertec Universal Medical Group Company Limited